Clinical applications of MR spectroscopy in epilepsy

Neuroimaging Clinics of North America

Volumn 14, Issue 3, 2004, Pages 507-516

  Kuzniecky, Ruben ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; GLUTAMIC ACID; GLUTAMINE; N ACETYLASPARTIC ACID;

ACCURACY; BRAIN LEVEL; BRAIN MAPPING; BRAIN METABOLISM; BRAIN SURGERY; CLINICAL PRACTICE; DISEASE ASSOCIATION; ELECTROENCEPHALOGRAPHY; HUMAN; IMAGE ANALYSIS; IMAGE PROCESSING; IMAGE QUALITY; NEUROIMAGING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; PROTON NUCLEAR MAGNETIC RESONANCE; REVIEW; SEIZURE; SIGNAL NOISE RATIO; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TEMPORAL LOBE EPILEPSY; TREATMENT OUTCOME; TREATMENT PLANNING;

AMINO ACIDS; BRAIN; EPILEPSY, TEMPORAL LOBE; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; NEUROTRANSMITTER AGENTS;

EID: 8444245537     PISSN: 10525149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nic.2004.04.010     Document Type: Review

References (97)

1. Connelly A., et al. Proton spectroscopy in the investigation of intractable temporal lobe epilepsy. Abstracts of the 11th annual meeting of the Society of Magnetic Resonance in Medicine. Berlin, Germany, 1992
2. Suhy J., et al. 1H MRSI predicts surgical outcome in MRI-negative temporal lobe epilepsy. Neurology. 58(5):2002;821-823
3. Eberhardt K.E., et al. The significance of bilateral CSI changes for the postoperative outcome in temporal lobe epilepsy. J Comput Assist Tomogr. 24(6):2000;919-926
4. Prichard J.W., et al. Cerebral metabolic studies in vivo by 31P NMR. Proc Natl Acad Sci USA. 80:1983;2748-2751
5. Petroff O.A., et al. In vivo phosphorus nuclear magnetic resonance spectroscopy in status epilepticus. Ann Neurol. 16:1984;169-177
6. Younkin D.P., et al. Cerebral metabolic effects of neonatal seizures measured with in vivo 31P NMR spectroscopy. Ann Neurol. 20:1986;513-519
7. Prichard J.W., et al. Cerebral lactate elevation by electroshock: a 1H magnetic resonance study. Ann N Y Acad Sci. 508:1987;54-63
8. Petroff O., et al. Cerebral lactate turnover after electroshock: in vivo measurements by 1H/13C MRS. J Cereb Blood Flow Metab. 12(6):1992;1022-1029
9. Maton B.M., et al. Postictal in situ MRS brain lactate in the rat kindling model. Neurology. 53(9):1999;2045-2052
10. Cendes F., et al. Lateralization of temporal lobe epilepsy based on regional metabolic abnormalities in proton MRS. Ann Neurol. 35:1994;211-216
11. Cendes F., et al. Proton magnetic resonance spectroscopic imaging and magnetic resonance imaging volumetry in the lateralization of temporal lobe epilepsy: a series of 100 patients. Ann Neurol. 42(5):1997;737-746
12. Hetherington H., et al. Proton nuclear magnetic resonance spectroscopic imaging of human temporal lobe epilepsy at 4.1 T. Ann Neurol. 38(3):1995;396-404
13. Hugg J.W., et al. Neuron loss localizes human temporal lobe epilepsy by in vivo proton magnetic resonance spectroscopic imaging. Ann Neurol. 34:1993;788-794
14. Li L.M., et al. Lateralization of temporal lobe epilepsy (TLE) and discrimination of TLE from extra-TLE using pattern analysis of magnetic resonance spectroscopic and volumetric data. Epilepsia. 41(7):2000;832-842
15. Cross H., et al. Proton MRS in children with temporal lobe epilepsy. Ann Neurol. 39:1995;107-113
16. Holopainen I.E., et al. Proton spectroscopy in children with epilepsy and febrile convulsions. Pediatr Neurol. 19(2):1998;93-99
17. Maton B.M., Kuzniecky R.I. Proton MRS: N-acetyl aspartate, creatine, and choline. Adv Neurol. 83:2000;253-259
18. Novotny E., Ashwal S., Shevell M. Proton magnetic resonance spectroscopy: an emerging technology in pediatric neurology research. Pediatr Res. 44(1):1998;1-10
19. Matthews P.M., Arnold D.L. Magnetic resonance imaging of multiple sclerosis: new insights linking pathology to clinical evolution. Curr Opin Neurol. 14(3):2001;279-287
20. Kuzniecky R., et al. Relative utility of 1H spectroscopic imaging and hippocampal volumetry in the lateralization of mesial temporal lobe epilepsy. Neurology. 51(1):1998;66-71
21. Connelly A., et al. Proton magnetic resonance spectroscopy in MRI-negative temporal lobe epilepsy. Neurology. 51(1):1998;61-66
22. Choi C., Frahm D. Localized proton MRS of the human hippocampus: metabolite concentrations and relaxation times. Magn Reson Imaging. 41:1999;204-207
23. Duncan J. Magnetic resonance spectroscopy. Epilepsia. 37(7):1996;598-605
24. Hsu Y.Y., et al. Proton chemical shift imaging of the hippocampus in patients with complex partial seizures. Changgeng Yi Xue Za Zhi. 22(1):1999;68-75
25. Laxer K.D. Clinical applications of magnetic resonance spectroscopy. Epilepsia. 38(Suppl 4):1997;S13-S17
26. Scott R.C., et al. Quantitative magnetic resonance characterization of mesial temporal sclerosis in childhood. Neurology. 56(12):2001;1659-1665
27. Cendes F., et al. Proton MRSI and MRI volumetry in the lateralization of temporal lobe epilepsy: a series of 100 patients. Ann Neurol. 42:1997;737-746
28. Hugg J., et al. Contralateral metabolic recovery following temporal lobectomy. Ann Neurol. 40:1996;236-239
29. Kuzniecky R., et al. Magnetic resonance spectroscopic imaging in temporal lobe epilepsy: neuronal dysfunction or cell loss? Arch Neurol. 58(12):2001;2048-2053
30. Bernasconi A., et al. Proton magnetic resonance spectroscopic imaging suggests progressive neuronal damage in human temporal lobe epilepsy. Prog Brain Res. 135:2002;297-304
31. Serles W., et al. Time course of postoperative recovery of N-acetyl-aspartate in temporal lobe epilepsy. Epilepsia. 42(2):2001;190-197
32. He H., Shen T., Chen X. Comparison of (1)H MRS, PET and EEG in lateralization of temporal lobe epilepsy [in Chinese]. Zhonghua Yi Xue Za Zhi. 81(20):2001;1242-1245
33. Knowlton R., et al. Presurgical multimodality neuroimaging in EEG lateralized temporal lobe epilepsy. Ann Neurol. 42:1997;829-837
34. Stanley J.A., et al. Proton magnetic resonance spectroscopic imaging in patients with extratemporal epilepsy. Epilepsia. 39(3):1998;267-273
35. Bernasconi A., et al. EEG background delta activity in temporal lobe epilepsy: correlation with volumetric and spectroscopic imaging. Epilepsia. 40(11):1999;1580-1586
36. Woermann F.G., et al. Short echo time single-voxel 1H magnetic resonance spectroscopy in magnetic resonance imaging-negative temporal lobe epilepsy: different biochemical profile compared with hippocampal sclerosis. Ann Neurol. 45(3):1999;369-376
37. Mueller S.G., et al. Reduced extrahippocampal NAA in mesial temporal lobe epilepsy. Epilepsia. 43(10):2002;1210-1216
38. Vermathen P., et al. Hippocampal structures: anteroposterior N-acetylaspartate differences in patients with epilepsy and control subjects as shown with proton MR spectroscopic imaging. Radiology. 214(2):2000;403-410
39. Cendes F., et al. MR Spectroscopy differentiates lactate in complex partial versus absence seizures. Ann Neurol. 41:1997;74-81
40. Ende G.R., et al. Temporal lobe epilepsy: bilateral hippocampal metabolite changes revealed at proton MR spectroscopic imaging. Radiology. 202(3):1997;809-817
41. Connelly A., et al. Magnetic resonance spectroscopy in temporal lobe epilepsy. Neurology. 44(8):1994;1411-1417
42. Levesque M., et al. Surgical treatment of limbic epilepsy associated with extrahippocampal lesions: the problem of dual pathology. J Neurosurg. 75:1991;364-370
43. Margerison J.H., Corsellis J.A.N. Epilepsy and the temporal lobes: a clinical electrographic and neuropathologidal study of the brain in epilepsy, with particular reference to the temporal lobes. Brain. 89:1966;499-530
44. Quigg M., et al. Volumetric magnetic resonance imaging evidence of bilateral hippocampal atrophy in mesial temporal lobe epilepsy. Epilepsia. 38(5):1997;588-594
45. Barr W.B., Ashtari M., Schaul N. Bilateral reductions in hippocampal volume in adults with epilepsy and a history of febrile seizures. J Neurol Neurosurg Psychiatry. 63(4):1997;461-467
46. Stefan H., et al. MRI spectroscopy, T2 relaxometry, and postoperative prognosis in cryptogenic temporal lobe epilepsy [in German]. Nervenarzt. 71(4):2000;282-287
47. Kuzniecky R., et al. Quantitative MRI in temporal lobe epilepsy: evidence for fornix atrophy. Neurology. 53(3):1999;496-501
48. Arnold D.L., De Stefano N. Magnetic resonance spectroscopy in vivo: applications in neurological disorders. Ital J Neurol Sci. 18(6):1997;321-329
49. Rabinowicz A.L., et al. Changes in regional cerebral blood flow beyond the temporal lobe in unilateral temporal lobe epilepsy. Epilepsia. 38(9):1997;1011-1014
50. Cendes F., et al. Imaging of axonal damage in vivo in Rasmussen's syndrome. Brain. 118(Pt 3):1995;753-758
51. Meiners L.C., et al. Proton magnetic resonance spectroscopy of temporal lobe white matter in patients with histologically proven hippocampal sclerosis. J Magn Reson Imaging. 11(1):2000;25-31
52. Kuzniecky R., Jackson G. Neuroimaging in epilepsy. Magnetic resonance in epilepsy. 1995;27-48 Raven Press, New York
53. Savic I., et al. In vivo measurements of glutamine + glutamate (Glx) and N-acetyl aspartate (NAA) levels in human partial epilepsy. Acta Neurol Scand. 102(3):2000;179-188
54. Garcia P.A., et al. Proton magnetic resonance spectroscopic imaging in patients with frontal lobe epilepsy. Ann Neurol. 37(2):1995;279-281
55. Burtscher I.M., Holtas S. Proton magnetic resonance spectroscopy in brain tumours: clinical applications. Neuroradiology. 43(5):2001;345-352
56. Simone I.L., et al. Metabolic changes in neuronal migration disorders: evaluation by combined MRI and proton MR spectroscopy. Epilepsia. 40(7):1999;872-879
57. Kuzniecky R., et al. Proton spectroscopic imaging at 4.1 tesla in patients with malformations of cortical development and epilepsy. Neurology. 48(4):1997;1018-1024
58. Antozzi C., et al. Epilepsia partialis continua associated with NADH-coenzyme Q reductase deficiency. J Neurol Sci. 129(2):1995;152-161
59. Kuzniecky R., et al. Proton MRSI at 4.1T in patients with malformations of cortical development. Neurology. 48:1997;1018-1024
60. Li L.M., et al. Neuronal metabolic dysfunction in patients with cortical developmental malformations: a proton magnetic resonance spectroscopic imaging study. Neurology. 50(3):1998;755-759
61. van der Grond J., et al. Regional distribution of interictal 31P metabolic changes in patients with temporal lobe epilepsy. Epilepsia. 39(5):1998;527-536
62. Laxer K.D. Phosphorus MRS: pH, ATP, PCr. Adv Neurol. 83:2000;273-277
63. Chu W., et al. Is the intracellular pH different from normal in the epileptic focus of patients with temporal lobe epilepsy? A 31P NMR study. Neurology. 47:1996;756-760
64. Gadian D.G. Proton NMR studies of brain metabolism. Phil Trans R Soc Lond A. 333:1990;561-570
65. Chu W.J., et al. Lateralization of human temporal lobe epilepsy by 31P NMR spectroscopic imaging at 4.1 T. Neurology. 51(2):1998;472-479
66. Hugg J.W., et al. Lateralization of human focal epilepsy by 31P magnetic resonance spectroscopic imaging. Neurology. 42(10):1992;2011-2018
67. Kuzniecky R., et al. In vivo 31P nuclear magnetic resonance spectroscopy of human temporal lobe epilepsy. Neurology. 42(8):1992;1586-1590
68. Hugg J.W., et al. Phosphorus-31 MR spectroscopic imaging (MRSI) of normal and pathological human brains. Magn Reson Imaging. 10(2):1992;227-243
69. Sherwin A.L. Neuroactive amino acids in focally epileptic human brain: a review. Neurochem Res. 24(11):1999;1387-1395
70. Bradford H.F. Glutamate, GABA and epilepsy. Prog Neurobiol. 47(6):1995;477-511
71. Kohling R. Neuroscience. GABA becomes exciting. Science. 298(5597):2002;1350-1351
72. Rothman D.L., et al. Localized 1H NMR measurements of gamma-aminobutyric acid in human brain in vivo. Proc Natl Acad Sci USA. 90(12):1993;5662-5666
73. Hyder F., et al. Localized 1H NMR measurements of 2-pyrrolidinone in human brain in vivo. Magn Reson Med. 41(5):1999;889-896
74. Shen J., Rothman D.L., Brown P. In vivo GABA editing using a novel doubly selective multiple quantum filter. Magn Reson Med. 47(3):2002;447-454
75. Hanstock C.C., Coupland N.J., Allen P.S. GABA X2 multiplet measured pre- and post-administration of vigabatrin in human brain. Magn Reson Med. 48(4):2002;617-623
76. Terpstra M., Ugurbil K., Gruetter R. Direct in vivo measurement of human cerebral GABA concentration using MEGA-editing at 7 Tesla. Magn Reson Med. 47(5):2002;1009-1012
77. Menini C., Silva-Barrat C. The photosensitive epilepsy of the baboon. A model of generalized reflex epilepsy. Adv Neurol. 75:1998;29-47
78. Lloyd K.G., et al. Cerebrospinal fluid amino acid and monoamine metabolite levels of Papio papio: correlation with photosensitivity. Brain Res. 363(2):1986;390-394
79. Kasteleijn-Nolst Trenite D.G. Reflex seizures induced by intermittent light stimulation. Adv Neurol. 75:1998;99-121
80. Rimmer E.M., Milligan N.M., Richens A. A comparison of the acute effect of single doses of vigabatrin and sodium valproate on photosensitivity in epileptic patients. Epilepsy Res. 1(6):1987;339-346
81. Petroff O.A., et al. Homocarnosine and seizure control in juvenile myoclonic epilepsy and complex partial seizures. Neurology. 56(6):2001;709-715
82. Petroff O.A., Mattson R.H., Rothman D.L. Proton MRS: GABA and glutamate. Adv Neurol. 83:2000;261-271
83. Haglund M.M., et al. Changes in gamma-aminobutyric acid and somatostatin in epileptic cortex associated with low-grade gliomas. J Neurosurg. 77(2):1992;209-216
84. Marco P., et al. Inhibitory neurons in the human epileptogenic temporal neocortex. An immunocytochemical study. Brain. 119(Pt 4):1996;1327-1347
85. Spreafico R., et al. Cortical dysplasia: an immunocytochemical study of three patients. Neurology. 50(1):1998;27-36
86. Petroff A., et al. The effects of Gabapentin on brain GABA in patients with epilepsy. Ann Neurol. 39:1996;95-98
87. Kuzniecky R., et al. MRI volumetric analysis of fornix and mamillary bodies in partial epilepsy. Neurology. 46:1996;211-216
88. Ottersen O.P., Zhang N., Walberg F. Metabolic compartmentation of glutamate and glutamine: morphological evidence obtained by quantitative immunocytochemistry in rat cerebellum. Neuroscience. 46(3):1992;519-534
89. Danbolt N.C. Glutamate uptake. Prog Neurobiol. 65(1):2001;1-105
90. Sherwin A.L., van Gelder N.M. Amino acid and catecholamine markers of metabolic abnormalities in human focal epilepsy. Adv Neurol. 44:1986;1011-1032
91. Petroff O.A., et al. Neuronal and glial metabolite content of the epileptogenic human hippocampus. Ann Neurol. 52(5):2002;635-642
92. Woermann F.G., et al. Short echo time single-voxel 1H magnetic resonance spectroscopy in magentic resonance imaging-negative temporal lobe epilepsy: different biochemical profile compared with hippocampal sclerosis. Ann Neurol. 45:1999;369-376
93. Pan J.W., et al. Evaluation of multiple sclerosis by 1H spectroscopic imaging at 4.1 T. Magn Reson Med. 36(1):1996;72-77
94. Petroff O.A. GABA and glutamate in the human brain. Neuroscientist. 8(6):2002;562-573
95. Patel A.B., et al. Glutamine is the major precursor for GABA synthesis in rat neocortex in vivo following acute GABA-transaminase inhibition. Brain Res. 919(2):2001;207-220
96. 31P. Mag Reson Med. 7:1988;412-424
97. Kuzniecky R., et al. Modulation of cerebral GABA by topiramate, lamotrigine, and gabapentin in healthy adults. Neurology. 58(3):2002;368-372